Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -16.89 is 29% above its 5-year average of -23.93, around the middle of its 5-year range (-40.93–2.75).
70.09% below its 12-month average of -9.93.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.28.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-16.89
EARNINGS PER SHARE (EPS) AVG TTM
-9.93
EARNINGS PER SHARE (EPS) AVG 3Y
-18.45
EARNINGS PER SHARE (EPS) AVG 5Y
-23.93
EARNINGS PER SHARE (EPS) AVG 10Y
-24.69
EARNINGS PER SHARE (EPS) AVG 15Y
-35.68
EARNINGS PER SHARE (EPS) AVG 20Y
-62.30
CURRENT VS TTM AVG
-70.09%
CURRENT VS 3Y AVG
+8.47%
CURRENT VS 5Y AVG
+29.41%
CURRENT VS 10Y AVG
+31.60%
CURRENT VS 15Y AVG
+52.66%
CURRENT VS 20Y AVG
+72.89%
ProMIS Neurosciences, Inc.
Market Cap
$81.88M
Earnings Per Share (EPS)
-16.89
TTM Avg
-9.93
3Y Avg
-18.45
5Y Avg
-23.93
Market Cap
$82.40M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$81.15M
Earnings Per Share (EPS)
-1.51
TTM Avg
-0.45
3Y Avg
-0.34
5Y Avg
-0.27
Market Cap
$82.69M
Earnings Per Share (EPS)
-0.22
TTM Avg
-0.23
3Y Avg
-0.23
5Y Avg
-0.24
Market Cap
$80.83M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
Market Cap
$80.53M
Earnings Per Share (EPS)
-0.57
TTM Avg
-1.79
3Y Avg
-1.21
5Y Avg
-1.06
Market Cap
$83.62M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$84.14M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $81.88M | -16.89 | -9.93 | -18.45 | -23.93 |
| Humacyte, Inc. (HUMA)vs › | $82.40M | -0.51 | -0.76 | -0.68 | -1.48 |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $81.15M | -1.51 | -0.45 | -0.34 | -0.27 |
| MediciNova, Inc. (MNOV)vs › | $82.69M | -0.22 | -0.23 | -0.23 | -0.24 |
| LENSAR Inc (LNSR)vs › | $82.78M | N/A | -2.80 | -2.22 | -2.13 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.83M | -1.88 | -2.06 | -2.07 | -1.66 |
| Nutriband Inc. (NTRB)vs › | $80.53M | -0.57 | -1.79 | -1.21 | -1.06 |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.62M | -0.60 | -0.82 | -0.86 | -0.88 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.14M | -0.19 | -0.58 | -0.69 | -0.67 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.25M | -1.18 | -4.40 | -32.48 | -54.06 |
Trailing EPS (TTM)
$-16.89
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -22.61 |
| 2024-12-31 | 2.75 |
| 2023-12-31 | -35.50 |
| 2021-12-31 | -40.93 |
| 2020-12-31 | -23.34 |
| 2019-12-31 | -32.98 |
| 2018-12-31 | -34.26 |
| 2017-12-31 | -27.81 |
| 2016-12-31 | -16.91 |
| 2015-12-31 | -15.35 |
| 2014-03-31 | -57.10 |
| 2013-03-31 | -57.03 |
| 2012-03-31 | -60.95 |
| 2011-03-31 | -77.48 |
| 2010-03-31 | -98.56 |
| 2009-03-31 | -115.39 |
| 2008-03-31 | -193.54 |
| 2007-03-31 | -218.37 |
| 2006-03-31 | -169.38 |
| 2006-03-31 | -107.40 |
| 2005-03-31 | -23.55 |
